Titre :
  • HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Auteur : Di Leo, Angelo ; Chan, S ; Paesmans, Marianne ; Friedrichs, Kay ; Pinter, Tamas ; Cocquyt, Veronique ; Murray, Elizabeth ; Bodrogi, István ; Walpole, Euan ; Lesperance, Bernard ; Korec, Stefan ; Crown, John ; Simmonds, Peter ; Von Minckwitz, G ; Leroy, Jean-Yves ; Durbecq, Virginie ; Isola, Jorma ; Aapro, Matti ; Piccart-Gebhart, Martine ; Larsimont, Denis
Informations sur la publication : Breast cancer research and treatment, 86, 3, (page 197-206)
Statut de publication : Publié, 2004-08
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés : c-erb B-2
p-53
topoisomerase II alpha
Mots-clés MeSH : Adolescent
Adult
Aged
Antibiotics, Antineoplastic -- administration & dosage
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- genetics
Breast Neoplasms -- pathology
Doxorubicin -- administration & dosage
Doxorubicin -- therapeutic use
Female
Genes, erbB-2
Genetic Markers
Humans
In Situ Hybridization, Fluorescence
Male
Middle Aged
Patient Selection
Predictive Value of Tests
Retrospective Studies
Survival Analysis
Taxoids -- administration & dosage
Taxoids -- therapeutic use
Treatment Outcome
Note : Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0167-6806 
info:doi/10.1023/B:BREA.0000036783.88387.47
info:pii/5265412
info:pmid/15567936